Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus

Lupus

Volumn 15, Issue 11_suppl, 2006, Pages 59-69

  McMahon, M ^a   Grossman, J ^a   Chen, W ^a   Hahn, B H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; inflammation; oxidized LDL; plaque; SLE

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL MATURATION; CHOLESTEROL TRANSPORT; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FOAM CELL; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

EID: 84994311347     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203306071668     Document Type: Review

References (150)

1. Ross R., Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Hansson GK., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
3. Hansson GK., Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
4. Kume N, Cybulsky MI, Gimbrone MA Jr,. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138-1144.
5. Watson AD, Leitinger N, Navab M, et al.Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272: 13597-13607.
6. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM., Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
7. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ., Highdensity lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-1994.
8. Calabresi L, Franceschini G, Sirtori CR, et al.Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65.
9. Barter PJ, Baker PW, Rye KA., Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13: 285-288.
10. Springer TA., Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995; 57: 827-872.
11. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD., The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102: 145-152.
12. Blankenberg S, Barbaux S, Tiret L., Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
13. Mehra VC, Ramgolam VS, Bender JR., Cytokines and cardiovascular disease. J Leukoc Biol 2005; 78: 805-818.
14. Roman MJ, Shanker BA, Davis A, et al.Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
15. Wang JM, Sica A, Peri G, et al.Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1166-1174.
16. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D., Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 1996; 16: 673-677.
17. Cushing SD, Berliner JA, Valente AJ, et al.Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134-5138.
18. Mackay CR., Chemokine receptors and T cell chemotaxis. J Exp Med 1996; 184: 799-802.
19. Gu L, Okada Y, Clinton SK, et al.Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
20. Boring L, Gosling J, Chensue SW, et al.Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100: 2552-2561.
21. Larsson PT, Hallerstam S, Rosfors S, Wallen NH., Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol 2005; 24: 43-51.
22. Navab M, Berliner JA, Watson AD, et al.The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
23. Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G., Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis 1988; 8: 368-377.
24. Navab M, Hama SY, Cooke CJ, et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494.
25. Navab M, Imes SS, Hama SY, et al.Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.
26. Navab M, Fogelman AM, Berliner JA, et al.Pathogenesis of atherosclerosis. Am J Cardiol 1995; 76: 18C-23C.
27. Hunt BJ., The endothelium in atherogenesis. Lupus 2000; 9: 189-193.
28. Steinberg D., Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
29. Podrez EA, Poliakov E, Shen Z, et al.Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 2002; 277: 38503-38516.
30. Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M., Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost 1997; 78: 195-199.
31. Remaley AT, Thomas F, Stonik JA, et al.Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003; 44: 828-836.
32. Shah PK, Yano J, Reyes O, et al.High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103: 3047-3050.
33. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR., Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003; 278: 37368-37374.
34. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ., Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003; 108: 661-663.
35. Navab M, Hama S, Hough G, Fogelman AM., Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 2003; 108: 1735-1739.
36. Navab M, Hama SY, Anantharamaiah GM, et al.Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
37. Navab M, Ananthramaiah GM, Reddy ST, et al.The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1007.
38. Shih DM, Gu L, Xia YR, et al.Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
39. Watson AD, Navab M, Hama SY, et al.Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-782.
40. Forte TM, Subbanagounder G, Berliner JA, et al.Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 2002; 43: 477-485.
41. Van Lenten BJ, Hama SY, de Beer FC, et al.Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767.
42. Gabay C, Kushner I., Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
43. Frostegard J, Ulfgren AK, Nyberg P, et al.Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
44. Uyemura K, Demer LL, Castle SC, et al.Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138.
45. Hauer AD, Uyttenhove C, de Vos P, et al.Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005; 112: 1054-1062.
46. Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW., Gammainterferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res 1988; 63: 712-719.
47. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E., Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem 2000; 275: 22895-22904.
48. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH., Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21: 713-758.
49. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C., IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761.
50. Whitman SC, Ravisankar P, Daugherty A., IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res 2002; 22: 661-670.
51. Fernandes JL, Mamoni RL, Orford JL, et al.Increased Th1 activity in patients with coronary artery disease. Cytokine 2004; 26: 131-137.
52. Saren P, Welgus HG, Kovanen PT., TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157: 4159-4165.
53. Wadham C, Albanese N, Roberts J, et al.High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109: 2116-2122.
54. Semb H, Peterson J, Tavernier J, Olivecrona T., Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987; 262: 8390-8394.
55. Ehnholm C, Aho K, Huttunen JK, et al.Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982; 2: 68-73.
56. Filonzi EL, Zoellner H, Stanton H, Hamilton JA., Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis 1993; 99: 241-252.
57. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S., Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-2142.
58. Barath P, Cao J, Forrester JS., Low density lipoprotein activates monocytes to express tumor necrosis factor. FEBS Lett 1990; 277: 180-184.
59. Haddy N, Sass C, Droesch S, et al.IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-283.
60. Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S., Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 2004; 172: 299-308.
61. Lindmark E, Diderholm E, Wallentin L, Siegbahn A., Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
62. Ridker PM., High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
63. Pasceri V, Cheng JS, Willerson JT, Yeh ET., Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
64. Rovere P, Peri G, Fazzini F, et al.The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000; 96: 4300-4306.
65. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM., High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001; 103: 2283-2288.
66. Liuzzo G, Biasucci LM, Gallimore JR, et al.The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
67. Biasucci LM, Vitelli A, Liuzzo G, et al.Elevated levels of interleukin- 6 in unstable angina. Circulation 1996; 94: 874-877.
68. Dessein PH, Joffe BI, Singh S., Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-R643.
69. Tsimikas S, Brilakis ES, Miller ER, et al.Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
70. Svenungsson E, Jensen-Urstad K, Heimburger M, et al.Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
71. Frostegard J, Svenungsson E, Wu R, et al.Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192-200.
72. Doria A, Shoenfeld Y, Wu R, et al.Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-1077.
73. Lee HS, Kim YS., Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998; 54: 848-856.
74. Kamanna VS, Pai R, Roh DD, Kirschenbaum MA., Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest 1996; 74: 1067-1079.
75. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK., Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-3163.
76. Salonen JT, Yla-Herttuala S, Yamamoto R, et al.Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
77. Hulthe J, Bokemark L, Fagerberg B., Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001; 21: 101-107.
78. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T., Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
79. Aho K, Vaarala O, Tenkanen L, et al.Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 499-506.
80. Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL, von Scheven E., Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004; 51: 451-457.
81. Gomez-Zumaquero JM, Tinahones FJ, De Ramon E, Camps M, Garrido L, Soriguer FJ., Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford) 2004; 43: 510-513.
82. Romero FI, Amengual O, Atsumi T, Khamashta MA, Tinahones FJ, Hughes GR., Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998; 37: 883-888.
83. Hayem G, Nicaise-Roland P, Palazzo E, et al.Anti-oxidized lowdensity- lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001; 10: 346-351.
84. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin JH., Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000; 97: 1743-1748.
85. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T., Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
86. Kobayashi K, Kishi M, Atsumi T, et al.Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 44: 716-726.
87. Kobayashi K, Matsuura E, Liu Q, et al.A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001; 42: 697-709.
88. Wityk RJ, Kittner SJ, Jenner JL, et al.Lipoprotein (a) and the risk of ischemic stroke in young women. Atherosclerosis 2000; 150: 389-396.
89. Wityk RJ, Kittner S., Lipoprotein(a) and the risk of stroke. Stroke 2000; 31: 1194-1195.
90. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U., Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-592.
91. Niendorf A, Rath M, Wolf K, et al.Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol 1990; 417: 105-111.
92. Tsimikas S, Bergmark C, Beyer RW, et al.Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41: 360-370.
93. Sari RA, Polat MF, Taysi S, Bakan E, Capoglu I., Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002; 21: 520-524.
94. Borba EF, Santos RD, Bonfa E, et al.Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-223.
95. Okawa-Takatsuji M, Aotsuka S, Sumiya M, Ohta H, Kawakami M, Sakurabayashi I., Clinical significance of the serum lipoprotein(a) level in patients with systemic lupus erythematosus: its elevation during disease flare. Clin Exp Rheumatol 1996; 14: 531-536.
96. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y., Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999; 8: 220-226.
97. Sugatani J, Miwa M, Komiyama Y, Ito S., High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 1996; 13: 73-88.
98. O'Connell BJ, Genest J Jr,. High-density lipoproteins and endothelial function. Circulation 2001; 104: 1978-1983.
99. Zeiher AM, Schachinger V., Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Z Kardiol 1994; 83 (Suppl 4): 7-14.
100. Borba EF, Bonfa E., Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
101. McMahon MGJFJ, Ebling F, Dahlin-Lee E, et al.Proinflammatory high-density lipoprotien as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis & Rheumatism August 2006; 54 (8): 2541-2549.
102. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J., Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-2540.
103. Lahita RG, Rivkin E, Cavanagh I, Romano P., Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1566-1574.
104. Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG., Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998; 7: 355-360.
105. Ansell BJ, Navab M, Hama S, et al.Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
106. Vuilleumier N, Reber G, James R, et al.Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 353-360.
107. Mackness MI, Durrington PN, Mackness B., The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004; 4: 211-217.
108. Watson AD, Berliner JA, Hama SY, et al.Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
109. Delgado Alves J, Ames PR, Donohue S, et al.Antibodies to highdensity lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694.
110. Lambert M, Boullier A, Hachulla E, et al.Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000; 9: 299-300.
111. Milionis HJ, Daskalopoulou SS, Elisaf M, Mikhailidis DP., The predictive value of lipid markers in vascular disease. Curr Pharm Des 2005; 11: 2209-2224.
112. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R., Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359-363.
113. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, et al.High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 160-165.
114. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC., Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033-1040.
115. Goldberg IJ., Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707.
116. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M., Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2957-2963.
117. de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfa E., Antilipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50: 3610-3615.
118. Beutler BA, Cerami A., Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985; 135: 3969-3971.
119. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J., TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 454-461.
120. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP., Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84: 1273-1278.
121. Schachinger V, Britten MB, Zeiher AM., Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
122. El-Magadmi M, Bodill H, Ahmad Y, et al.Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
123. Navarro M, Cervera R, Font J, et al.Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997; 6: 521-526.
124. Clancy RM, Buyon JP., Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol 2003; 74: 959-960.
125. Rajagopalan S, Somers EC, Brook RD, et al.Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-3683.
126. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK., Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102: 2576-2581.
127. Wang J, Qiang H, Zhang C, Liu X, Chen D, Wang S., Detection of IgGbound lipoprotein(a) immune complexes in patients with coronary heart disease. Clin Chim Acta 2003; 327: 115-122.
128. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF., Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002; 105: 81-92.
129. Bellosta S, Corsini A, Bernini F, et al.27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells. FEBS Lett 1993; 332: 115-118.
130. Corsini A, Verri D, Raiteri M, Quarato P, Paoletti R, Fumagalli R., Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol 1995; 15: 420-428.
131. Reiss AB, Awadallah NW, Malhotra S, et al.Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001; 42: 1913-1922.
132. Yeh ET., CRP as a mediator of disease. Circulation 2004; 109 (21 Suppl 1): II11-II14.
133. Torzewski J, Torzewski M, Bowyer DE, et al.C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-1392.
134. Zwaka TP, Hombach V, Torzewski J., C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-1197.
135. Manzi S, Selzer F, Sutton-Tyrrell K, et al.Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
136. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al.Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151-159.
137. Schonbeck U, Libby P., CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
138. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK., Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073.
139. Kotowicz K, Dixon GL, Klein NJ, Peters MJ, Callard RE., Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 2000; 100: 441-448.
140. Mach F, Schonbeck U, Sukhova GK, et al.Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
141. Schonbeck U, Mach F, Bonnefoy JY, Loppnow H, Flad HD, Libby P., Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J Biol Chem 1997; 272: 19569-19574.
142. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM., Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
143. Yellin MJ, D'Agati V, Parkinson G, et al.Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997; 40: 124-134.
144. George J, Harats D, Gilburd B, et al.Adoptive transfer of beta(2)- glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822-1827.
145. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al.Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
146. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W., Immunization of LDL receptor-deficient mice with homologous malondialdehydemodified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-1982.
147. George J, Afek A, Gilburd B, et al.Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-152.
148. Nicolo D, Goldman BI, Monestier M., Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003; 48: 2974-2978.
149. Meroni PL, Borghi MO, Raschi E, et al.Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-334.
150. Cederholm A, Svenungsson E, Jensen-Urstad K, et al.Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198-203.